Zimmer Biomet Holdings (NYSE: ZBH) reported Q1 EPS of $2.13, $0.02 better than the analyst estimate of $2.11. Revenue for the quarter came in at $1.98 billion versus the consensus estimate of $1.96 billion.

"Zimmer Biomet delivered first quarter revenue and adjusted earnings growth consistent with our expectations, as we positioned the Company for sales acceleration in the second half of the year,\" said David Dvorak, President and CEO of Zimmer Biomet. \"During the quarter, we made progress towards improving our global supply chain throughput, in concert with ongoing, focused investments to harmonize and optimize our global manufacturing and quality systems. We will continue driving these priorities as we progress through the balance of 2017, while leveraging our specialized sales channels and advancing the commercialization of differentiated clinical offerings

GUIDANCE:

Zimmer Biomet Holdings sees Q2 2017 EPS of $8.50-$8.60, versus the consensus of $8.59.

For earnings history and earnings-related data on Zimmer Biomet Holdings (ZBH) click here.